BRAINLIFE.ORG




Current Neuro-Oncology




Volume 26 Number 2
31 January 2024




Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 2, 31 January






Drexler R, Brembach F, Sauvigny J, Ricklefs FL, Eckhardt A, Bode H, Gempt J, Lamszus K, Westphal M, Schüller U, Mohme M.
Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact.
Acta Neuropathol Commun. 2024 Jan 16;12(1):9. doi: 10.1186/s40478-024-01728-9. PMID: 38229158. Observational study. ˍ




Rynda AY, Rostovthev DM, Zabrodskaya YM, Olyushin VE.
Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas – results.
J Neurooncol. 2024 Jan 16;166(2):309-319. doi: 10.1007/s11060-023-04559-1. PMID: 38227144. Observational study˰ ˍ




Zhao B, Yao J, Wang J, Li J, Shi W, Zhang C, Zhao X, Qiao J, Ma Y, Xu Y, Zheng Z.
Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.
Neurol Sci. 2024 Jan 16. doi: 10.1007/s10072-024-07315-z. PMID: 38228940. Observational study˰ ˍ




*Ainslie AP, Klaver M, Voshart DC, Gerrits E, den Dunnen WFA, Eggen BJL, Bergink S, Barazzuol L.
Glioblastoma and its treatment are associated with extensive accelerated brain aging.
Aging Cell. 2024 Jan 17:e14066. doi: 10.1111/acel.14066. PMID: 38234228. Observational study. ˍ




Chaban A, Waschulzik B, Bernhardt D, Delbridge C, Schmidt-Graf F, Wagner A, Wiestler B, Weber W, Yakushev I.
Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy.
Eur J Nucl Med Mol Imaging. 2024 Jan 17. doi: 10.1007/s00259-024-06601-4. PMID: 38228970. Observational study. ˍ




Fariña-Jerónimo H, Martín-Ramírez R, González-Fernández R, Medina L, de Vera A, Martín-Vasallo P, Plata-Bello J.
Androgen deficiency is associated with a better prognosis in glioblastoma.
Eur J Med Res. 2024 Jan 17;29(1):57. doi: 10.1186/s40001-024-01648-3. PMID: 38233838. Observational study. ˍ




Krystal J, Hanson D, Donnelly D, Atlas M.
A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.
Pediatr Blood Cancer. 2024 Jan 17:e30874. doi: 10.1002/pbc.30874. PMID: 38234020. Interventional study˰ ˍ




Marastoni E, Ammendola S, Rossi S, Giovannoni I, Broggi G, Masotto B, Feletti A, Barresi V.
H3 K27M mutation in rosette-forming glioneuronal tumors: a potential diagnostic pitfall.
Virchows Arch. 2024 Jan 17. doi: 10.1007/s00428-024-03739-2. PMID: 38233563. Observational study. ˍ




Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon DA, Chang SM, Hervey-Jumper SL, Berger MS, Lupo JM, Okada H, Phillips JJ, Boutros PC, Gallo M, Oldham MC, Yue F, Costello JF.
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective.
Cell. 2024 Jan 18;187(2):446-463.e16. doi: 10.1016/j.cell.2023.12.013. PMID: 38242087. Laboratory investigation. ˍ
Related article:
Baig S, Winkler F.
A holistic view of the malignant organism we call glioblastoma.
Cell. 2024 Jan 18;187(2):271-273. doi: 10.1016/j.cell.2023.12.021. PMID: 38242083. Comment˰ ˍ




Heymer EJ, Hawkins MM, Winter DL, Teepen JC, Sunguc C, Ronckers CM, Allodji RS, Alessi D, Sugden E, Belle FN, Bagnasco F, Byrne J, Bárdi E, Garwicz S, Grabow D, Jankovic M, Kaatsch P, Kaiser M, Michel G, Schindera C, Haddy N, Journy N, Česen Mazić M, Skinner R, Kok JL, Gunnes MW, Wiebe T, Sacerdote C, Maule MM, Terenziani M, Jakab Z, Winther JF, Lähteenmäki PM, Zadravec Zaletel L, Haupt R, Kuehni CE, Kremer LC, de Vathaire F, Hjorth L, Reulen RC.
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02577-y. PMID: 38243010. Observational study. ˍ




*Karatsu K, Tamura R, Yo M, Nogawa H, Hino U, Kitamura Y, Ueda R, Toda M.
The Role of Genetic Analysis in Distinguishing Multifocal and Multicentric Glioblastomas: An Illustrative Case.
Case Rep Oncol. 2024 Jan 22;17(1):113-121. doi: 10.1159/000536051. PMID: 38260034. Case report. ˍ




Pepper NB, Eich HT, Müther M, Oertel M, Rehn S, Spille DC, Stummer W.
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Radiat Oncol. 2024 Jan 22;19(1):11. doi: 10.1186/s13014-024-02408-7. PMID: 38254201. Interventional study protocol. ˍ




Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes MB, Donahue J, Purow B, Dillon P, Le T, Schiff D, Liu Q, Lum LG.
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
J Neurooncol. 2024 Jan 23;166(2):321-330. doi: 10.1007/s11060-024-04564-y. PMID: 38263486. Interventional study. ˍ




Tang T, Wang Y, Dai Y, Liu Q, Fan X, Cheng Y, Tang J, Xiao X, Shan Y, Wei P, Zhao G.
IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults.
Pathol Res Pract. 2024 Jan 24;254:155165. doi: 10.1016/j.prp.2024.155165. PMID: 38286053. Observational study˰ ˍ




Dar MS, Shahid N, Waqas A, Baig YA, Khan AW.
Dabrafenib plus Trametinib: A breakthrough in pediatric low-grade glioma therapy.
Health Sci Rep. 2024 Jan 25;7(1):e1841. doi: 10.1002/hsr2.1841. PMID: 38274133. Interventional study. ˍ




Liao Y, Bai X, Cao Y, Zhang M.
Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.
J Clin Neurosci. 2024 Jan 25;120:196-203. doi: 10.1016/j.jocn.2024.01.018? PMID: 38277995. Observational study. ˍ




Lu Y, Liao L, Du K, Mo J, Zou X, Liang J, Chen J, Tang W, Su L, Wu J, Zhang J, Tan Y.
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
BMC Cancer. 2024 Jan 25;24(1):133. doi: 10.1186/s12885-024-11848-z. PMID: 38273249. Observational study. ˍ




Heuer S, Burghaus I, Gose M, Kessler T, Sahm F, Vollmuth P, Venkataramani V, Hoffmann D, Schlesner M, Ratliff M, Hopf C, Herrlinger U, Ricklefs F, Bendszus M, Krieg SM, Wick A, Wick W, Winkler F.
PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
BMC Cancer. 2024 Jan 26;24(1):135. doi: 10.1186/s12885-024-11846-1. PMID: 38279087. Interventional study protocol. ˍ




Kameda-Smith MM, Ragulojan M, Elliott C, Bliss L, Moore H, Sader N, Alsuwaihel M, Tso MK, Dakson A, Ajani O, Yarascavitch B, Fleming A, Mehta V, Aminnejad M, Farrokhyar F, Singh SK; McMaster Pediatric Brain Tumour Study Group (PBTSG) and the Canadian Neurosurgery Research Collaborative (CNRC).
National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.
Childs Nerv Syst. 2024 Jan 27. doi: 10.1007/s00381-024-06292-0. PMID: 38279985. Observational study˰ ˍ




Yekula A, Gessler DJ, Ferreira C, Shah R, Reynolds M, Dusenbery K, Chen CC.
GammaTile® (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials.
J Neurooncol. 2024 Jan 28. doi: 10.1007/s11060-023-04545-7. PMID: 38281303. Observational study˰ ˍ




Fiveash JB, Ye X, Peerboom DM, Mikkelsen T, Chowdhary S, Rosenfeld M, Lesser GJ, Fisher J, Desideri S, Grossman S, Leopold L, Nabors LB.
Clinical trials of R-(-)-gossypol (AT-101) in newly diagnosed and recurrent glioblastoma: NABTT 0602 and NABTT 0702.
PLoS One. 2024 Jan 29;19(1):e0291128. doi: 10.1371/journal.pone.0291128. PMID: 38285688. Interventional study. ˍ




Shenoy G, Slagle-Webb B, Khunsriraksakul C, Pandya Shesh B, Luo J, Khristov V, Smith N, Mansouri A, Zacharia BE, Holder S, Lathia JD, Barnholtz-Sloan JS, Connor JR.
Analysis of anemia and iron supplementation among glioblastoma patients reveals sex-biased association between anemia and survival.
Sci Rep. 2024 Jan 29;14(1):2389. doi: 10.1038/s41598-024-52492-8. PMID: 38287054. Observational study. ˍ




van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martínez O, Zápotocký M, Scheinemann K, Meeteren AYNS, Sehested A, Opocher E, Driever PH, Avula S, Ziegler DS, Capper D, Koch A, Sahm F, Qiu J, Tsao LP, Blackman SC, Manley P, Milde T, Witt R, Jones DTW, Hargrave D, Witt O.
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
BMC Cancer. 2024 Jan 30;24(1):147. doi: 10.1186/s12885-024-11820-x. PMID: 38291372. Interventional study protocol. ˍ




Habashy KJ, Dmello C, Chen L, Arrieta VA, Kim KS, Gould A, Youngblood MW, Bouchoux G, Bell Burdett KB, Zhang H, Canney M, Stupp R, Sonabend AM.
Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma.
Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2367. PMID: 38295144. Observational study˰ ˍ




Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama Y, Miyake K, Sasaki H.
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544-8. PMID: 38291182. Interventional study. ˍ